Ascentage Pharma Group International AAPG

What this company does

Ascentage Pharma discovers, develops and commercializes therapies for cancer. Olverembatinib, a third-generation tyrosine kinase inhibitor, was the first BCR-ABL1 inhibitor approved in China for chronic myeloid leukemia in chronic phase with T315I mutations, chronic myeloid leukemia in accelerated phase with T315I mutations, and chronic-phase disease resistant to or intolerant of first- and second-generation tyrosine kinase inhibitors, and the company commercializes it in China. Lisaftoclax was approved in China by the NMPA for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who had previously received at least one systemic therapy including BTK inhibitors, in July 2025, and the company began commercializing it in China shortly after receiving approval. In 2025, the company's commercial team covered more than 1,500 hospitals and over 800 pharmacies for its two commercialized products, and it established strategic partnerships with pharmaceutical distributors for nationwide drug distribution coverage.

Written from the business description in ASCENTAGE PHARMA GROUP INTERNATIONAL's annual report to the U.S. Securities and Exchange Commission, filed 29 April 2026. Every sentence was checked against that document before publication.